BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 38029929)

  • 1. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
    Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
    Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.
    Iqbal J; Wu HX; Hu N; Zhou YH; Li L; Xiao F; Wang T; Jiang HL; Xu SN; Huang BL; Zhou HD
    Obes Rev; 2022 Jun; 23(6):e13435. PubMed ID: 35194917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
    Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
    Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
    Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
    Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
    Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
    Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
    Hu EH; Tsai ML; Lin Y; Chou TS; Chen TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
    Drab SR
    Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.
    Widiarti W; Sukmajaya AC; Nugraha D; Alkaff FF
    Diabetes Metab Syndr; 2021; 15(3):837-843. PubMed ID: 33866119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.
    Xie W; Hong Z; Li B; Huang B; Dong S; Cai Y; Ruan L; Xu Q; Mou L; Zhang Y
    J Diabetes Complications; 2024 Jun; 38(6):108743. PubMed ID: 38688179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
    Cai W; Zhang R; Yao Y; Wu Q; Zhang J
    Front Public Health; 2024; 12():1277113. PubMed ID: 38356942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
    Madsbad S; Holst JJ
    Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.